Glaxosmithkline Share News (GSK)

IN BRIEF: Destiny Pharma picks interim CEO as Clark makes quick exit

Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology company focused on preventing life-threatening infections - Chief Executive Officer Neil Clark steps down immediately "to pursue new challenges". Clark will "support [Destiny] for a limited period to ensure an orderly handover." Non-Executive Director Debra Barker will serve as interim CEO until Destiny appoints a permanent replacement. Barker has held "key roles" at Novartis AG and Polyphor AG, now named Spexis AG. She also has previously worked at Roche Holding AG, Polyneuron Pharmaceuticals AG and GSK PLC.

US Supreme Court rejects Teva challenge to $235 million GSK award in patent dispute

WASHINGTON, May 15 (Reuters) - The U.S. Supreme Court on Monday declined to hear Teva Pharmaceuticals USA Inc's challenge to a $235 million award to GlaxoSmithKline LLC in a patent dispute over generic drugs involving a heart medication.

US Supreme Court rejects Teva challenge to $235 million GSK award in patent dispute

WASHINGTON, May 15 (Reuters) - The U.S. Supreme Court on Monday declined to hear Teva Pharmaceuticals USA Inc's challenge to a $235 million award to GlaxoSmithKline LLC in a patent dispute over generic drugs involving a heart medication.

LONDON MARKET CLOSE: Sterling slides after weak UK GDP print

(Alliance News) - Stocks in London ended the week broadly higher on Friday, with strong performances from blue-chips Beazley and GSK helping to offset weak economic growth data for the UK economy.

LONDON MARKET MIDDAY: FTSE 100 outperforms as Beazley, GSK shine

(Alliance News) - Stock prices in London were mixed at midday on Friday as investors digested a weak GDP reading for the UK, a day after the Bank of England took the country's interest rates up to a 15-year-high.

GSK hails 5-in-1 meningococcal ABCWY vaccine candidate trial data

(Alliance News) - GSK PLC on Friday reported positive preliminary results from a phase 3 trial regarding its 5-in-1 meningococcal ABCWY vaccine candidate.

GSK sells $1 bln discounted stake in spin-off Haleon

GSK sells 240 mln Haleon shares at discount

*

Canadian court dismisses GSK Zantac litigation

(Sharecast News) - A proposed class action against GSK has been dismissed by a court in Canada, the UK drugs giant confirmed on Friday.

TOP NEWS: GSK welcomes legal ruling in Canada; sells Haleon shares

(Alliance News) - GSK PLC on Friday welcomed a legal ruling in Canada that threw out a proposed class action made on behalf of users of a heartburn drug.

GSK sells 2.4% of Haleon stake via placing for £804m

(Sharecast News) - UK pharmaceuticals company GSK said it had sold a 2.5% stake in Haleon at 335p a share, raising £804m.

LONDON BRIEFING: No Apollo offer for THG; GSK trims Haleon stake

(Alliance News) - Stocks in London were called to open higher on Friday, after data showed the UK economy expanded 0.1% over the first three months of the year.

LONDON BRIEFING: Shell sets USD4 billion buyback; Next backs outlook

(Alliance News) - Stocks in London were called to open lower on Thursday, amid a busy day for company earnings and an interest rate decision by the EU's central bank in the afternoon.

IN BRIEF: GSK receives FDA approval for Arexvy in older adults

GSK PLC - Brentford, London-based pharmaceutical firm - Announces the US Food & Drug Administration approves Arexvy, the world's first respiratory syncytial virus vaccine for older adults. States approval enables adults aged 60 years and older to be protected from RSV disease for the first time. Explains the approval is based on data from the positive pivotal AReSVi-006 phase III trial that showed exceptional efficacy in older adults, including those with underlying medical conditions, and in those with severe RSV disease. Plans US launch before the 2023/24 RSV season.

London stocks gain ahead of Fed rate decision; Lloyds drags

Coca Cola HBC AG rises on upbeat forecast

*

LONDON MARKET CLOSE: FTSE 100 in the green ahead of Fed rate decision

(Alliance News) - Stocks in London were higher at the close on Wednesday as investor waited with bated breath for the US Federal Reserve's next interest rate decision.